{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:57:12Z","timestamp":1793890632811,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["5R25CA020449"],"award-info":[{"award-number":["5R25CA020449"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jtho.2023.12.019","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T07:07:57Z","timestamp":1703574477000},"page":"732-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-8803","authenticated-orcid":false,"given":"Igor","family":"Odintsov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisam","family":"Makarem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Emily","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"LoPiccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafulla C.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romel","family":"Somwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.12.019_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jtho.2023.12.019_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(03)00048-0","article-title":"The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors","volume":"11","author":"Garrett","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtho.2023.12.019_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2023.12.019_bib4","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ng.2760","article-title":"Pan-cancer patterns of somatic copy number alteration","volume":"45","author":"Zack","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2023.12.019_bib5","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1097\/JTO.0000000000000379","article-title":"NSCLC and HER2: between lights and shadows","volume":"9","author":"Ricciardi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.lungcan.2014.06.007","article-title":"HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations","volume":"85","author":"Yoshizawa","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.12.019_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdh031","article-title":"Randomized phase II trial of gemcitabine\u2013cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","volume":"15","author":"Gatzemeier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3816\/CLC.2004.n.004","article-title":"Trastuzumab plus docetaxel in HER2\/neu\u2013positive non\u2013small-cell lung cancer: a California cancer consortium screening and Phase II trial","volume":"5","author":"Lara","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2023.12.019_bib10","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1002\/cncr.21428","article-title":"Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma","volume":"104","author":"Krug","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2023.12.019_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2003.09.026","volume":"44","author":"Zinner","year":"2004","journal-title":"Lung Cancer Amst, Neth"},{"key":"10.1016\/j.jtho.2023.12.019_bib12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2004.04.105","article-title":"Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598","volume":"22","author":"Langer","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/cncr.20950","article-title":"Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B","volume":"103","author":"Clamon","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2023.12.019_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2023.12.019_bib15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2023.12.019_bib16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2023.12.019_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2 -Mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jtho.2023.12.019_bib18","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jtho.2021.01.285","article-title":"OA04.05 trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01","volume":"16","author":"Nakagawa","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtho.2023.12.019_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2023.12.019_bib21","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41379-022-01083-x","article-title":"Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations","volume":"35","author":"Siegmund","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2023.12.019_bib22","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ajcp\/aqz031","article-title":"Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma","volume":"152","author":"Cenaj","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtho.2023.12.019_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2023.12.019_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2023.12.019_bib26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jtho.2021.03.013","article-title":"Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and mTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers","volume":"16","author":"Odintsov","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-Impact): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jtho.2023.12.019_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor Receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jtho.2023.12.019_bib29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/0008-5472.CAN-21-1397","article-title":"CIC-mediated modulation of MAPK signaling opposes receptor tyrosine kinase inhibitor response in kinase-addicted sarcoma","volume":"82","author":"Odintsov","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2023.12.019_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jnci\/59.1.221","article-title":"One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude Mice23","volume":"59","author":"Fogh","year":"1977","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"suppl 24","key":"10.1016\/j.jtho.2023.12.019_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcb.240630505","article-title":"NCI-navy medical oncology branch cell line data base","volume":"63","author":"Phelps","year":"1996","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jtho.2023.12.019_bib32","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1158\/1078-0432.CCR-20-3605","article-title":"The anti-HER3 mAb Seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions","volume":"27","author":"Odintsov","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2023.12.019_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-022-01041-x","article-title":"Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology","volume":"14","author":"Adib","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2023.12.019_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, Phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib35","article-title":"Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: results from the targeted agent and profiling utilization registry study","volume":"7","author":"Ganti","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/2159-8290.CD-17-1004","article-title":"Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.12.019_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.12.019_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and\u00a0safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2023.12.019_bib39","article-title":"Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: results from a phase 2 basket trial (HERALD\/EPOC1806)","volume":"41","author":"Taniguchi","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.12.019_bib40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.12.019_bib41","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2023.12.019_bib42","article-title":"Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC","volume":"4","author":"Jebbink","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2023.12.019_bib43","doi-asserted-by":"crossref","first-page":"20139","DOI":"10.1073\/pnas.2007474117","article-title":"An ErbB2 splice variant lacking exon 16 drives lung carcinoma","volume":"117","author":"Smith","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2023.12.019_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtho.2023.12.019_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.6004\/jnccn.2023.7010","article-title":"HER2 targeting in esophagogastric cancer: redefining the landscape and breaking barriers","volume":"21","author":"Cytryn","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2023.12.019_bib46","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","article-title":"Detection of\u00a0ERBB2 amplification in uterine serous carcinoma by\u00a0next-generation sequencing: an approach highly concordant with standard assays","volume":"34","author":"Robinson","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423024280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423024280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T13:27:55Z","timestamp":1746106075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423024280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1556086423024280"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.12.019","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}